Dupilumab, Eczema Immunomodulatory Therapies May Not Increase Risk of Severe COVID-19
International investigators observe differing levels of severe COVID-19 risk for patients with atopic dermatitis, dependent on their current therapy.
Ruxolitinib Cream Provides Significant Vitiligo Facial, Body Repigmentation at 52 Weeks
Data from the phase 3 TRuE-V clinical program show the topical JAK inhibitor provided substantial repigmentation to more than half of treated patients.
Baricitinib Efficacious for Hair Regrowth in Alopecia Areata
Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.
Dupilumab Improves Itch and Lesions in Patients with Prurigo Nodularis
Dupilumab is the first biologic to show positive phase 3 results in patients with prurigo nodularis.
Dermatologists Diagnose Psoriasis Less Frequently in Black Patients
A Perelman School of Medicine assessment of biopsy rates support previous findings showing that dermatologists are less confident making psoriasis diagnoses in patients with darker skin color.
Awaiting FDA Decision on Ruxolitinib Cream for Vitiligo
John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.
Data Suggests Lower COVID-19 Incidence in Dupilumab-Treated AD Patients
New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.
The Promising Future of Vitiligo Treatment
John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.
Atopic Dermatitis Linked to Increased Risk of Select Cancers
The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.
Roflumilast Cream Significantly Benefits Psoriasis Severity, Itch in Phase 3 DERMIS Trials
New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.
The Society for Pediatric Dermatology's 2022 Annual Pre-AAD Meeting
Dr. Elena B. Hawryluk details her pre-AAD session, the variety of conversations being held at the meeting, and how these conversations can inform dermatological research outside of the pediatric field.
Alopecia Severity Linked to Worse Patient Quality of Life Perspective
A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.
JAKs of All Trades: What The Drug Class Means for Dermatology
While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.
Insights into the Bimekizumab Clinical Trial Program
Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.
Dermatologic Reactions to the COVID-19 Vaccine
Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.
Biologic Therapy Not Linked to Worse COVID-19 Infection, Death Risks
A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.
Real-World Dupilumab Initiation Linked to Atopic Dermatitis Clearance at 6 Months
An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.
Secukinumab Provides Psoriasis Skin Clearance Regardless of Psoriatic Arthritis Status
A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.
What Are The Best, Safest Systemic Therapies for Atopic Dermatitis?
A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.
What Role Would Bimekizumab Play for Plaque Psoriasis?
The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.
Ligelizumab Superior to Omalizumab for Chronic Spontaneous Urticaria Clearance
The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.
Benzoyl Peroxide Plus Retinol Regimen Highly Efficacious for Acne Vulgaris
All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.
Balancing Integrative and Conventional Approaches to Dermatologic Care
Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.
Dermatology’s Shifting Landscape for Patients of Color
Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.
How Ruxolitinib Cream Could Fit into Modern Dermatologic Care Strategies
Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.
Age, Gender, Disease Severity Influence Dermatology-Related Depression
New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.
What Experts Hope Ruxolitinib Cream Could Provide Atopic Dermatitis
The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.
Guselkumab May Provide Benefit for Psoriatic Arthritis Across Multiple Domains
A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.
Ixekizumab Linked to Rapid Pediatric Psoriasis Clearance
Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.
Assessing the Value of Integrative Dermatology
In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.